Last week, Bristol Myers Squibb (BMS; NYSE: BMY) unveiled preliminary results from a Phase III confirmatory trial for its KRAS inhibitor Krazati (adagrasib) in patients with pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying a KRASG12C mutation. This encouraging data reinforces BMS’s strategic 2023 acquisition of original developer Mirati Therapeutics.
The company reported that the study successfully met both primary and secondary endpoints, demonstrating statistically significant improvements in progression-free survival (PFS) and overall response rate (ORR), with no new safety concerns identified. The trial will proceed to gather additional overall survival (OS) data.
Provisional approvals for Krazati have been granted in the markets of the European Union (EU), UK, and US, contingent on the results from this pivotal study.- Flcube.com
